Citius Pharmaceuticals is trading at $0.69 (+9.2%) in pre-market, extending a sharp multi-day rally. The momentum follows strong investor reaction to fiscal Q2 2026 results, reporting $1.7 million in quarterly LYMPHIR net revenue and $5.6 million for the first half of fiscal 2026. Further support comes from recent updates on LYMPHIR's commercialization, including the nationwide deployment of a broadened commercial organization, as of July 21, 2026.